MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
0.5951
-0.0249
-4.02%
After Hours: 0.5951 0 0.00% 19:30 11/20 EST
OPEN
0.6001
PREV CLOSE
0.6200
HIGH
0.6139
LOW
0.5719
VOLUME
933.40K
TURNOVER
--
52 WEEK HIGH
1.720
52 WEEK LOW
0.5719
MARKET CAP
36.89M
P/E (TTM)
-0.4068
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (1109-1113)?
Weekly Report · 6d ago
RBC Capital Remains a Hold on Pliant Therapeutics (PLRX)
TipRanks · 11/13 16:56
Press Release: Pliant Therapeutics Provides -2-
Dow Jones · 11/12 21:05
Weekly Report: what happened at PLRX last week (1102-1106)?
Weekly Report · 11/09 10:06
Weekly Report: what happened at PLRX last week (1026-1030)?
Weekly Report · 11/02 10:06
Weekly Report: what happened at PLRX last week (1019-1023)?
Weekly Report · 10/26 10:06
Press Release: Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Dow Jones · 10/20 12:30
Weekly Report: what happened at PLRX last week (1012-1016)?
Weekly Report · 10/19 10:06
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.